Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

THE IN VIVO AND IN VITRO METABOLIC PROFILE OF 99MTC-NC100668, A NEW TRACER FOR IMAGING VENOUS THROMBOEMBOLISM: IDENTIFICATION AND BIODISTRIBUTION OF THE PRINCIPAL RADIOLABELED METABOLITE

David Edwards, Mark Battle, Rochelle Lear, Gill Farrar, D. Jon Barnett, Vanessa Godden, Catherine Coombes, Alexandra Oliveira and Håkan Ahlström
Drug Metabolism and Disposition July 2006, 34 (7) 1128-1135; DOI: https://doi.org/10.1124/dmd.106.009696
David Edwards
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Battle
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rochelle Lear
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gill Farrar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Jon Barnett
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vanessa Godden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Coombes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandra Oliveira
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Håkan Ahlström
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

99mTc-NC100668 [Acetyl-Asn-Gln-Glu-Gln-Val-Ser-Pro-Tyr(3-iodo)-Thr-Leu-Leu-Lys-Gly-NC100194] is a radiopharmaceutical imaging agent being developed to aid the diagnosis of thromboembolism. The stability profile of 99mTc-NC100668 was investigated by high-performance liquid chromatography (HPLC) after in vitro exposure to blood and plasma obtained from rat and human, as well as to urine and bile obtained from rat. The metabolic profile of 99mTc-NC100668 exposed to human and rat hepatic S9 (a liver homogenate-rich cytochrome P450) was also studied. The profile of 99mTc-labeled species in plasma, urine, and bile was investigated following i.v. administration of 99mTc-NC100668 to rat. The major species observed in vitro and in vivo consisted of the 99mTc-chelator (NC100194) [N,N-Bis(N-(1,1-dimethyl-2-(hydroxylimino-)propyl)aminoethyl)aminoethylamine] attached to the C-terminal amino acid residue and referred to as 99mTc-complex of Gly-NC100194. The identity of the major metabolite was confirmed by cochromatography with an authentic standard and the genuine metabolite using a second HPLC method. The minor metabolites were sodium pertechnetate (99mTc) and 99mTc-NC100194. In addition, a small number of other species were transiently observed in vitro; they were not investigated further. The biodistribution of the major metabolite was studied in male Wistar rats. The affinity of the major metabolite toward plasma clot was established using a plasma clot-forming assay. A minor uptake of 99mTc-complex of Gly-NC100194 in the plasma clot and a rapid removal from the body were noted. In conclusion, the metabolites of 99mTc-NC100668 are not anticipated to have a negative impact on the ability of the test substance to image blood clots.

Footnotes

  • Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

  • doi:10.1124/dmd.106.009696.

  • ABBREVIATIONS: NC100668, Acetyl-Asn-Gln-Glu-Gln-Val-Ser-Pro-Tyr(3-iodo)-Thr-Leu-Leu-Lys-Gly-NC100194; FXIIIa, factor XIIIa; RCP, radiochemical purity; TRODAT, ethanethiol, 2-[[2-[[[(1R,2R,3S,5S)-3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3.2.1]oct-2-yl]methyl](2-mercaptoethyl)amino]ethyl]amino]; HPLC, high-performance liquid chromatography; NC100194, N,N-Bis(N-(1,1-dimethyl-2-(hydroxylimino)propyl)aminoethyl)aminoethylamine; ITLC, instant thin layer chromatography; TFA, trifluoroacetic acid; RHT, reduced hydrolyzed technetium; MDP, methylene diphosphonic acid; DTPA, diethylenetriaminepentaacetic acid; % id, percentage of injected dose.

    • Received February 6, 2006.
    • Accepted April 5, 2006.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 34 (7)
Drug Metabolism and Disposition
Vol. 34, Issue 7
1 Jul 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
THE IN VIVO AND IN VITRO METABOLIC PROFILE OF 99MTC-NC100668, A NEW TRACER FOR IMAGING VENOUS THROMBOEMBOLISM: IDENTIFICATION AND BIODISTRIBUTION OF THE PRINCIPAL RADIOLABELED METABOLITE
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

THE IN VIVO AND IN VITRO METABOLIC PROFILE OF 99MTC-NC100668, A NEW TRACER FOR IMAGING VENOUS THROMBOEMBOLISM: IDENTIFICATION AND BIODISTRIBUTION OF THE PRINCIPAL RADIOLABELED METABOLITE

David Edwards, Mark Battle, Rochelle Lear, Gill Farrar, D. Jon Barnett, Vanessa Godden, Catherine Coombes, Alexandra Oliveira and Håkan Ahlström
Drug Metabolism and Disposition July 1, 2006, 34 (7) 1128-1135; DOI: https://doi.org/10.1124/dmd.106.009696

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

THE IN VIVO AND IN VITRO METABOLIC PROFILE OF 99MTC-NC100668, A NEW TRACER FOR IMAGING VENOUS THROMBOEMBOLISM: IDENTIFICATION AND BIODISTRIBUTION OF THE PRINCIPAL RADIOLABELED METABOLITE

David Edwards, Mark Battle, Rochelle Lear, Gill Farrar, D. Jon Barnett, Vanessa Godden, Catherine Coombes, Alexandra Oliveira and Håkan Ahlström
Drug Metabolism and Disposition July 1, 2006, 34 (7) 1128-1135; DOI: https://doi.org/10.1124/dmd.106.009696
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Warfarin PBPK Model with TMDD Mechanism
  • Identification of payload-containing catabolites of ADCs
  • PK Interactions of Licorice with Cytochrome P450s
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics